**IN THE CLAIMS**

Please cancel claim 24 without prejudice.

Please amend claim 42 as follows:

1-14. (Cancelled)

15. (Previously Presented) A vaccine formulation suitable for mucosal administration comprising:

(a) a mixture of a first vaccine antigen which is Hepatitis B virus surface antigen (HBsAg), and

(b) a second vaccine antigen which is a viral nucleocapsid or a virus-like particle; wherein said HBsAg has an adjuvant effect on the second vaccine antigen, and wherein said first and second vaccine antigens are each present from 0.001mg to 1mg.

16. (Previously Presented) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is the nucleocapsid antigen of Hepatitis B virus.

17. (Previously Presented) The vaccine formulation according to claim 15, wherein the virus-like particle is the virus-like particle antigen of Human Papilloma virus (HPV).

18. (Previously Presented) The vaccine formulation according to claim 15, wherein the viral nucleocapsid is the nucleocapsid antigen of Hepatitis C virus.

19-20. (Cancelled)

21. (Previously Presented) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for nasal administration.

22. (Previously Presented) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis B virus (HBV) infection.

23. (Previously Presented) The vaccine formulation according to claim 15, wherein the vaccine formulation is suitable for use as a preventive vaccine against Hepatitis B virus (HBV) infection.

24. (Cancelled)

25. (Previously Presented) The vaccine formulation according to claim 17, wherein the vaccine formulation is suitable for use as a preventive vaccine against Human Papilloma virus (HPV) infection.

26. (Previously Presented) The vaccine formulation according to claim 18, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Hepatitis C virus (HCV) infection.

27. (Previously Presented) The vaccine formulation according to claim 17, wherein the vaccine formulation is suitable for use as a therapeutic vaccine against Human Papilloma virus (HPV) infection.

28-37. (Cancelled)

38. (Previously Presented) A vaccine formulation suitable for mucosal administration, comprising:

(a) a mixture of a first vaccine antigen which is Hepatitis B virus surface antigen (HBsAg), and

(b) a second vaccine antigen and a third vaccine antigen,

wherein the vaccine antigens are each present from 0.001mg to 1mg.

39. (Previously Presented) The vaccine formulation according to claim 38, wherein the second vaccine antigen is an antigen of a viral nucleocapsid or a virus-like particle.

40. (Previously Presented) The vaccine formulation according to claim 39, wherein the virus-like particle is the virus-like particle antigen of Human Papilloma Virus (HPV).

41. (Previously Presented) The vaccine formulation according to claim 39, wherein the third vaccine antigen is Hepatitis B virus core antigen (HBcAg).

42. (Currently Amended) A method for administering a vaccine antigen which is a viral nucleocapsid or a virus-like particle, the method comprising ~~treating or preventing a viral infection comprising~~ administering mucosally a vaccine formulation according to claim 15.